Study Title

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study in Patients With Prostate Cancer

Study Details

Description:

68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-NI-093 PET/CT in patients with prostate cancer.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Government Study Link:

NCT06612580 - Click here to see study on

ClinicalTrials.gov

Drug Details

68Ga-AAZTA-NI-093
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • PSMA

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468